Efficacy of Neurotropin for Chronic Low Back Pain: A Retrospective Observational Study

Introduction: This study aimed to evaluate pain outcomes after Neurotropin initiation in individuals with chronic low back pain (CLBP) and to explore factors associated with treatment response. Methods: This multicenter retrospective observational study included patients with CLBP (duration ≥3 months) who received oral Neurotropin therapy (4 tablets daily) from May 2024 to May 2025. The primary outcome was pain intensity, measured using a visual analog scale (VAS) at baseline and at 2, 4, 8, and 12 weeks. The secondary outcomes were patient characteristics, pain features, simplified Spine painDETECT questionnaire scores, and Brief Scale for Psychiatric Problems in Orthopaedic Patients (BS-POP) scores. Statistical analyses were conducted using paired t-tests with Bonferroni correction, repeated-measures analysis of variance, and multivariate regression. Results: A total of 106 patients (46 males, 60 females; mean age: 66.5±15.8 years) were included. The baseline VAS score was 6.74±1.12. Neurotropin was associated with significant pain reduction over 12 weeks, with VAS scores decreasing to 5.40±1.42 at 2 weeks, 5.15±1.39 at 4 weeks, 4.95±1.38 at 8 weeks, and 4.73±1.48 at 12 weeks (p